SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

46Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach. A secondary objective is to track newly developing SARS-CoV-2-targeting mAbs from first tests in humans onwards.

Cite

CITATION STYLE

APA

Kreuzberger, N., Hirsch, C., Chai, K. L., Piechotta, V., Valk, S. J., Estcourt, L. J., … Skoetz, N. (2021). SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database of Systematic Reviews, 2021(1). https://doi.org/10.1002/14651858.CD013825

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free